Oseltamivir shortens hospital stays of critically ill children hospitalized with seasonal influenza: A retrospective cohort study

Pediatric Infectious Disease Journal

Volumn 30, Issue 11, 2011, Pages 962-966

  Coffin, Susan E ^a,b   Leckerman, Kateri ^a   Keren, Ron ^a,b   Hall, Matthew ^c   Localio, Russell ^a   Zaoutis, Theoklis E ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Child Health Corporation of America   (United States)

Author keywords

child; epidemiology; influenza; oseltamivir; treatment

Indexed keywords

OSELTAMIVIR;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DATA BASE; DRUG EXPOSURE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HOSPITALIZED CHILD; HUMAN; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MORTALITY; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEASONAL INFLUENZA; TREATMENT OUTCOME; WINTER;

ANTIVIRAL AGENTS; CHILD, HOSPITALIZED; CHILD, PRESCHOOL; CRITICAL ILLNESS; DATABASES, FACTUAL; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HOSPITALS, PEDIATRIC; HUMANS; INFANT; INFLUENZA, HUMAN; INTENSIVE CARE UNITS, PEDIATRIC; LENGTH OF STAY; MALE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 80054991884     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318232ede9     Document Type: Article

References (36)

1. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children[comment]. New Engl J Med. 2006;355:31-40.
2. CDC. Influenza Activity-United States and Worldwide, May 18-September 19, 2008. MMWR. 2008;57:1046-1049.
3. Centers for Disease Control. Notifiable diseases/deaths in selected cities weekly information. MMWR. 2009;58:474-485.
4. Keren R, Zaoutis T, Bridges C, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. J Am Med Assoc. 2005;294:2188-2194. (Pubitemid 41571136)
5. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. New Engl J Med. 2005;353: 2559-2567. (Pubitemid 41785893)
6. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122:805-811.
7. Peebles PJ, Dhara R, Brammer L, et al. Influenza-associated mortality among children-United States: 2007-2008. Influenza Other Respi Viruses. 2011;5:25-31.
8. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children [Erratum in: Pediatr Infect Dis J. 2001;20:421]. Pediatr Infect Dis J. 2001;20:127-133. (Pubitemid 32151932)
9. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group [Erratum in: Lancet. 2000;356:1856]. Lancet. 2000;355:1845-1850. (Pubitemid 30311875)
10. Togo Y, Hornick RB, Felitti VJ, et al. Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA. 1970;211:1149-1156.
11. Lin JT, Yu XZ, Cui DJ, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006;22:75-82.
12. Sato M, Hosoya M, Kato K, et al. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J. 2005;24:931-932. (Pubitemid 41475935)
13. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group[comment]. JAMA. 2000;283:1016-1024. (Pubitemid 30112215)
14. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-1246. (Pubitemid 29468495)
15. Galbraith AW, Oxford JS, Schild GC, et al. Therapeutic effect of 1-adamantanamine hydrochloride in naturally occurring influenza A 2-Hong Kong infection. A controlled double-blind study. Lancet. 1971;2:113-115.
16. Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenzainfected children with asthma. Pediatr Infect Dis J. 2005;24:225-232. (Pubitemid 40365856)
17. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667-1672. (Pubitemid 36898954)
18. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized Patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009:NEJMoa0906695.
19. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada[see comment]. Clin Infect Dis. 2007;45:1568-1575. (Pubitemid 351411840)
20. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302:1880-1887.
21. Berry JG, Hall DE, Kuo DZ, et al. Hospital utilization and characteristics of patients experiencing recurrent readmissions within children's hospitals. JAMA. 2011;305:682-690.
22. Bucher BT, Guth RM, Saito JM, et al. Impact of hospital volume on in-hospital mortality of infants undergoing repair of congenital diaphragmatic hernia. Ann Surg. 2010;252:635-642.
23. Kronman MP, Hall M, Slonim AD, et al. Charges and lengths of stay attributable to adverse patient-care events using pediatric-specific quality indicators: a multicenter study of freestanding children's hospitals. Pediatrics. 2008;121:e1653-e1659.
24. Mongelluzzo J, Mohamad Z, Ten Have TR, et al. Corticosteroids and mortality in children with bacterial meningitis. JAMA. 2008;299:2048-2055. (Pubitemid 351656586)
25. Sobota A, Graham DA, Heeney MM, et al. Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission [Erratum in: Am J Hematol. 2010;85:399]. Am J Hematol. 2010;85:24-28.
26. Zaoutis T, Localio AR, Leckerman K, et al. Prolonged intravenous therapy versus early transition to oral antimicrobial therapy for acute osteomyelitis in children. Pediatrics. 2009;123:636-642.
27. Feudtner C, Christakis DA, Connell FA. Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington state, 1980-1997. Pediatrics. 2000;106:205-209. (Pubitemid 30436857)
28. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259.
29. Sturmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006;59:437-447.
30. Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika. 1983;70:41.
31. Griswold MEP, Localio ARP, Mulrow CMDM. Propensity Score Adjustment With Multilevel Data: Setting Your Sites on Decreasing Selection Bias. Ann Intern Med. 2010;152:393-395.
32. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33.
33. Collett D. Modelling Survival Data in Medical Research. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC; 1993.
34. Nordstrom BL, Sung I, Suter P, et al. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. Curr Med Res Opin. 2005;21:761-768. (Pubitemid 40695298)
35. Piedra PA, Schulman KL, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. Pediatrics. 2009;124:170-178.
36. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group[comment]. New Engl J Med. 1997;337:874-880. (Pubitemid 27408569)